Abstracts tagged "SLE"

Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Cristina Arriens¹, Rufei Lu², Teresa Aberle², Stan Kamp², Wade DeJager², Melissa E. Munroe², Eliza Chakravarty¹, Katherine Thanou², Joan T. Merrill³, Joel M. Guthridge⁴ and Judith A. James³, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…
Abstract Number: 2979 • 2017 ACR/ARHP Annual Meeting
The Expression of Mitochondrial Molecules in Microparticle Immune Complexes in the Blood of Patients with Systemic Lupus Erythematosus
Fariborz Mobarrez¹, Enrico Fuzzi¹, Iva Gunnarsson¹, David Pisetsky² and Elisabet Svenungsson¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Department of Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by immune complexes, especially those with nuclear molecules bound by antinuclear antibodies. Although the…
Abstract Number: 697 • 2017 ACR/ARHP Annual Meeting
Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity
Valentin S. Schäfer¹, Katharina Weiss², Andreas Krause² and Wolfgang A. Schmidt³, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: ESR is applied for monitoring disease activity in SLE. It is known to be influenced by age and infections. We aimed at evaluating how…
Abstract Number: 1585 • 2017 ACR/ARHP Annual Meeting
Role of Corticosteroids in Subclinical Atherosclerosis in SLE: A Systematic Review and Meta-Analysis
Ehsan Rajabirostami¹, Kam Newman², Sreelakshmi Panginikkod¹, Shahrzad Mohammadiankhansari¹, Nader Mehri³, Roshanak Habibi⁴ and Manish Jain⁵, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Rheumatology, Eisenhower Medical Center, Rancho Mirage, CA, ³Social Gerontology, Miami University, Oxford, OH, ⁴Presence Saint Francis Hospital, Evanston, IL, ⁵Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: Atherosclerosis in SLE results from a complex interplay between traditional risk factors, SLE-specific factors, chronic inflammation and multifaceted effects of SLE therapeutics. In particular,…
Abstract Number: 1811 • 2017 ACR/ARHP Annual Meeting
Lupus Patients, and Their Sisters, Have Higher Miscarriage Rates Than Healthy Women
Eliza Chakravarty¹, David Miklos², Nathan Pezant³, Fang Wu², Indra Adrianto⁴, R. Hal Scofield³, Joel M. Guthridge⁵, Courtney Montgomery⁴ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Hematology, Stanford University, Stanford, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects women during the childbearing years. Among its protean manifestation, pregnancy complications including…
Abstract Number: 2601 • 2017 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
Jie An¹, Weinan Lai^2,3, Joshua Woodward⁴, Xizhang Sun¹, Lena Tanaka¹, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine/Division of Rheumatology, University of Washington, Seattle, WA, ³Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres…
Abstract Number: 698 • 2017 ACR/ARHP Annual Meeting
Selected Nailfold Videocapillaroscopy Changes Are Linked to SLE Onset in a Cohort of Uctd Subjects
Marianna Meroni¹, Carmen Pizzorni², Alberto Sulli¹, Paola Rossi³, Paolo Stobbione³ and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ³Rheumatology Unit, Internal Medicine Department - A.O. S.S. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Nailfold capillaroscopy (NVC) is a useful, non-invasive, reproducible and cost-effective diagnostic tool, able to assess the shape of capillaries in the nailfold bed. According…
Abstract Number: 1586 • 2017 ACR/ARHP Annual Meeting
Resistant Hypertension Is Associated with Inflammation, Renal Function, and Increased Mortality in Patients with Systemic Lupus Erythematosus
Jocelyn Gandelman¹, Megan Shuey², April Barnado³, Li Wang⁴, C. Michael Stein³ and Cecilia P. Chung³, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Department of Pharmacology, Vanderbilt University, Nashville, TN, ³Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Resistant hypertension (RHTN) is defined as blood pressure that remains >140/90 mm Hg despite concurrent use of three different antihypertensive drugs. RHTN has an…
Abstract Number: 1834 • 2017 ACR/ARHP Annual Meeting
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Javier Rangel-Moreno¹, Jennifer Barnard², Shelton Cochran³, Margaret Lee³, Sharon Tamir³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for systemic lupus erythematosus (SLE), but the biologic therapies under investigation over the past several…
Abstract Number: 2611 • 2017 ACR/ARHP Annual Meeting
Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients
Brittaney-Belle E. Gordon¹, Katherine Kaufman², Sean T. Hicks¹, Julie A. Norfleet¹, Rebecca J. Cleveland¹, Leigh F. Callahan³ and Saira Z. Sheikh¹, ¹Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, ²Department of Pediatrics, Duke University School of Medicine, Durham, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Fatigue and arthritis are common sources of impairment in SLE patients that persist despite lifestyle and pharmacologic interventions. Walk with Ease (WWE) is the…
Abstract Number: 706 • 2017 ACR/ARHP Annual Meeting
Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity
George Stojan¹, Erik Barr² and Michelle Petri³, ¹Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and…
Abstract Number: 1597 • 2017 ACR/ARHP Annual Meeting
Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE
Kristin D'Silva¹, Ezra Cohen², David J. Kreps³, Mary Beth Son² and Karen H. Costenbader³, ¹Internal Medicine, Brigham and Women's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is an uncommon but potentially fatal complication of SLE. We conducted a case-control study comparing hospitalized adults with SLE with…
Abstract Number: 1835 • 2017 ACR/ARHP Annual Meeting
Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde¹, Philip J. Homan², Harris Perlman² and Carla Cuda², ¹Northwestern University, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Neuropsychiatric symptoms of systemic lupus erythematosus (NP-SLE), including headaches, cognitive dysfunction and psychiatric disorders, appear in up to 75% of SLE patients and may…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].